Vitekta (Elvitegravir) for HIV

Overview
Vitekta is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection in combination with Ritonavir and an antiretroviral medication of the protease inhibitor class. Vitekta is approved for use in adults who have already begun antiretroviral treatment for HIV infection. Vitekta is also referred to by its drug name, Elvitegravir, and by the abbreviation EVG. Elvitegravir is a component in the combination drugs Genvoya and Stribild.

Vitekta is an antiviral medication of the integrase strand transfer inhibitor (INSTI) class. Vitekta is believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Vitekta is taken once or twice daily. Vitekta comes in tablet form.

Side effects
The FDA-approved label for Vitekta lists common side effects including headache, nausea, and diarrhea. Rare but serious side effects listed for Vitekta include psychiatric disorders such as depression or suicidal ideation.

For more details about this treatment, visit:

Vitekta - RxList

Overview of HIV Treatments – AIDS.gov